BFM
ATNM icon

Boothbay Fund Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Boothbay Fund Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,135
Closed -$95.8K – 1805
2023
Q1 		$95.8K Buy
+10,135
New +$107K ﹤0.01% 1949
2018
Q3 		– Sell
-859
Closed -$16K – 785
2018
Q2 		$16K Buy
+859
New +$10.9K ﹤0.01% 726

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Boothbay Fund Management's ATNM Position: Q2 2023 in Review

Boothbay Fund Management sold out of Actinium Pharmaceuticals (ATNM) in Q2 2023, closing a stake of 10,135 shares — an estimated $95.8K sold.

Boothbay Fund Management first reported a position in ATNM in Q2 2018 and held it in 2 quarters. The position peaked at $95.8K in Q1 2023. 71 funds tracked by Wall St. Rank hold ATNM as of Q2 2023.

  • Boothbay Fund Management reported no remaining Actinium Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 10,135 Actinium Pharmaceuticals shares in Q2 2023, an estimated $95.8K.
  • Boothbay Fund Management first reported a position in Actinium Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Boothbay Fund Management's Actinium Pharmaceuticals position peaked at $95.8K in Q1 2023.
  • 71 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.